Patents by Inventor Jean-Loup Salzmann
Jean-Loup Salzmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9765304Abstract: The present invention relates to compositions and methods for producing an immune response or reaction, as well as to vaccines, kits, processes, cells and uses thereof. This invention more particularly relates to compositions and methods of using a synthetic viral particle to produce, modify or regulate an immune response in a subject. In a more preferred embodiment, the invention is based, generally, on compositions using synthetic viral particles as an adjuvant and/or vehicle to raise an immune response against selected antigen(s) or epitopes, in particular a cellular and/or a humoral immune response.Type: GrantFiled: January 24, 2014Date of Patent: September 19, 2017Assignee: L'Universite Pierre Et Marie CurieInventors: David Klatzmann, Jean-Loup Salzmann, Bertrand Bellier, Charlotte Fribert, Francois-Loic Cosset
-
Publication number: 20140255445Abstract: The present invention relates to compositions and methods for producing an immune response or reaction, as well as to vaccines, kits, processes, cells and uses thereof. This invention more particularly relates to compositions and methods of using a synthetic viral particle to produce, modify or regulate an immune response in a subject. In a more preferred embodiment, the invention is based, generally, on compositions using synthetic viral particles as an adjuvant and/or vehicle to raise an immune response against selected antigen(s) or epitopes, in particular a cellular and/or a humoral immune response.Type: ApplicationFiled: January 24, 2014Publication date: September 11, 2014Applicant: L'Universite Pierre Et Marie CurieInventors: David Klatzmann, Jean-Loup Salzmann, Bertrand Bellier, Charlotte Frisen, Francois-Loic Cosset
-
Patent number: 8673612Abstract: The present invention relates to compositions and methods for producing an immune response or reaction, as well as to vaccines, kits, processes, cells and uses thereof. This invention more particularly relates to compositions and methods of using a synthetic viral particle to produce, modify or regulate an immune response in a subject. In a more preferred embodiment, the invention is based, generally, on compositions using synthetic viral particles as an adjuvant and/or vehicle to raise an immune response against selected antigen(s) or epitopes, in particular a cellular and/or a humoral immune response.Type: GrantFiled: October 25, 2001Date of Patent: March 18, 2014Assignee: L'Universite Pierre et Marie CurieInventors: David Klatzmann, Jean-Loup Salzmann, Bertrand Bellier, Charlotte Frisen, François-Loïc Cosset
-
Patent number: 6872528Abstract: The invention concerns a packaging eukaryotic cell for the production of defective infections viruses carrying a transgene, characterized in that it is deficient in one cell function essential to its growth, in particular in the presence of a selection culture medium, the function being capable of being restored by the expression of an exogenous sequence introduced in the cell: either with a vector carrying transcomplementing functions of packaging cells; or with a vector carrying a transgene, and enabling the selection in a selective medium of cells carrying the said exogenous sequence.Type: GrantFiled: October 15, 2001Date of Patent: March 29, 2005Assignee: Universite Pierre et Marie CurieInventors: David Klatzmann, Jean-Loup Salzmann
-
Publication number: 20040071661Abstract: The present invention relates to compositions and methods for producing an immune response or reaction, as well as to vaccines, kits, processes, cells and uses thereof. This invention more particularly relates to compositions and methods of using a synthetic viral particle to produce, modify or regulate an immune response in a subject. In a more preferred embodiment, the invention is based, generally, on compositions using synthetic viral particles as an adjuvant and/or vehicle to raise an immune response against selected antigen(s) or epitopes, in particular a cellular and/or a humoral immune response.Type: ApplicationFiled: October 15, 2003Publication date: April 15, 2004Inventors: David Klatzmann, Jean-Loup Salzmann, Bertrand Bellier, Charlotte Frisen, Francois-Loic Cosset
-
Patent number: 6489142Abstract: The invention concerns methods and constructs for producing retroviral particles, in vitro, ex vivo or in vivo. It also concerns the use of said methods and constructs for transferring nucleic acids into cells. More particularly, the invention concerns a composition comprising the whole set of genetic elements required for constituting a retroviral particle, incorporated in one or several recombinant adenoviruses defective for all or part of the regions E1 and E4 at least (adenoviral/retroviral chimeric vectors).Type: GrantFiled: January 25, 2001Date of Patent: December 3, 2002Assignees: Aventis Pharma S.A., GenopoieticInventors: Christophe Torrent, Patrice Yeh, Michel Perricaudet, David Klatzmann, Jean-Loup Salzmann
-
Patent number: 6485965Abstract: The invention relates to the use of replicating or semi-replicating viral construct(s) for the preparation of a composition for gene delivery into cells in vivo, ex vivo or in vitro. The invention also relates to novel retroviral constructs, packaging cells and nucleic acids which can be used in methods of delivering polynucleotides to cells.Type: GrantFiled: June 8, 2000Date of Patent: November 26, 2002Inventors: David Klatzmann, Arnaud Morel, Georg Holzer, Jean-Loup Salzmann
-
Publication number: 20020123146Abstract: The invention concerns a packaging eukaryotic cell for the production of defective infections viruses carrying a transgene, characterized in that it is deficient in one cell function essential to its growth, in particular in the presence of a selection culture medium, the said function being capable of being restored by the expression of an exogenous sequence introduced in the cell: either with a vector carrying transcomplementing functions of packaging cells; or with a vector carrying a transgene, and enabling the selection in a selective medium of cells carrying the said exogenous sequence.Type: ApplicationFiled: October 15, 2001Publication date: September 5, 2002Applicant: Universite Pierre et Marie CurieInventors: David Klatzmann, Jean-Loup Salzmann
-
Publication number: 20020051763Abstract: The invention relates to a system for expressing a transgene in a target cell or a human or animal cell, characterized in that it consists of a eukaryotic cell established as a line, into which there have been transfected:Type: ApplicationFiled: May 6, 1999Publication date: May 2, 2002Inventors: DAVID KLATZMANN, JEAN-LOUP SALZMANN
-
Patent number: 6365405Abstract: This invention concerns compositions of chondrocytic cells, notably human ones, and the methods for preparing and using them. More specifically, the invention describes the production of autologous human chondrocyte suspensions, employing recombinant enzymes and/or media that are compatible with pharmaceutical use. The invention also describes methods and compositions for freezing chondrocytes, notably in the absence of DMSO. The chondrocytes which are produced can be used in vivo to restore affected cartilaginous structures, such as in post-traumatic cartilaginous defects or dissecting osteochondrite of the knee or, more generally, for treating and repairing clinically significant defects in cartilage, notably in joint cartilage.Type: GrantFiled: September 15, 2000Date of Patent: April 2, 2002Assignee: Universite Pierre et Marie Curie (Paris IV)Inventors: Jean-Loup Salzmann, Andrès Crespo, David Klatzmann, Norbert Passuti
-
Patent number: 6140114Abstract: The present invention relates to a vaccine consisting of defective viral particles as are obtained in vivo or ex vivo, in individuals infected or capable of being infected with a virus, after expression of the genes carried by a vector or a combination of vectors and comprising at least the structural genes necessary for the constitution of the viral particle.Type: GrantFiled: October 5, 1998Date of Patent: October 31, 2000Assignee: Universite Pierre et Marie Curie (Paris VI)Inventors: David Klatzmann, Jean-Loup Salzmann
-
Patent number: 6090378Abstract: Composition for use in the treatment of tumors and the immunization of humans or animals comprising a synergistic association of cells, viruses, or bacteria expressing, transitorily, in organisms at least one gene for producing in vivo one or more immunomodulators, and viruses, or cells producing viruses, said viruses preferably infecting dividing cells of the treated organisms and carrying within their genome at least one gene whose expression in the dividing cells will cause their destruction.Type: GrantFiled: July 16, 1997Date of Patent: July 18, 2000Assignees: Institut Pasteur, Institut National de la Sante et de la Recherche Medicale, Universite Pierre et Marie Curie, Assistance Publique-Hopitaux de ParisInventors: Claude Roth, Philippe Kourilsky, Lluis Mir, David Klatzmann, Jean-Loup Salzmann
-
Patent number: 5948675Abstract: The invention relates to a system for expressing a transgene in a target cell or a human or animal cell, characterized in that it consists of a eukaryotic cell established as a line, into which there have been transfected:a) a recombinant viral sequence in which a gene has been deleted totally or partially and substituted by the transgene at the level of this gene;b) a nucleic acid sequence including a sequence encoding the deleted protein, which sequence is in dependence on a promoter and is combined, where appropriate, with the transgene, and flanked at its 3' end a polyadenylation site;the recombinant viral genome and the sequence, carried by one or two plasmid supports, being capable of trans-complementing each other and allowing the host cell to produce defective infectious viruses.Type: GrantFiled: October 4, 1996Date of Patent: September 7, 1999Assignee: Universite Pierre et Marie Curie (Paris VI)Inventors: David Klatzmann, Jean-Loup Salzmann
-
Patent number: 5906939Abstract: A cultured eukaryotic cell dissociation method using at least one polysaccharide polymer derivative. In particular, the method of dissociating cultured, adherent fibroblast or epithelial cells using a chelating agent such as EDTA and a sulfated polysaccharide such as heparin is disclosed.Type: GrantFiled: May 2, 1997Date of Patent: May 25, 1999Assignee: Universite Pierre Et Marie Curie (Paris VI)Inventor: Jean-Loup Salzmann